SG11202005036RA - Anti-pd-l1 antibody and il-7 fusions - Google Patents

Anti-pd-l1 antibody and il-7 fusions

Info

Publication number
SG11202005036RA
SG11202005036RA SG11202005036RA SG11202005036RA SG11202005036RA SG 11202005036R A SG11202005036R A SG 11202005036RA SG 11202005036R A SG11202005036R A SG 11202005036RA SG 11202005036R A SG11202005036R A SG 11202005036RA SG 11202005036R A SG11202005036R A SG 11202005036RA
Authority
SG
Singapore
Prior art keywords
fusions
antibody
Prior art date
Application number
SG11202005036RA
Inventor
Lei Fang
Feifei Cui
Haijuan Gu
Zhengyi Wang
Bingshi Guo
Jingwu Zang
Original Assignee
I Mab Biopharma Us Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Us Ltd filed Critical I Mab Biopharma Us Ltd
Publication of SG11202005036RA publication Critical patent/SG11202005036RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
SG11202005036RA 2018-01-25 2019-01-25 Anti-pd-l1 antibody and il-7 fusions SG11202005036RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018074121 2018-01-25
PCT/CN2019/073264 WO2019144945A1 (en) 2018-01-25 2019-01-25 Anti-pd-l1 antibody and il-7 fusions

Publications (1)

Publication Number Publication Date
SG11202005036RA true SG11202005036RA (en) 2020-06-29

Family

ID=67395659

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005036RA SG11202005036RA (en) 2018-01-25 2019-01-25 Anti-pd-l1 antibody and il-7 fusions

Country Status (14)

Country Link
US (1) US11401331B2 (en)
EP (1) EP3568417A4 (en)
JP (2) JP7102670B2 (en)
KR (1) KR20200058322A (en)
CN (1) CN110352202A (en)
AU (2) AU2019203918B2 (en)
BR (1) BR112020010536A2 (en)
CA (1) CA3082975A1 (en)
EA (1) EA202091054A1 (en)
IL (1) IL274564A (en)
MX (1) MX2020005193A (en)
SG (1) SG11202005036RA (en)
WO (1) WO2019144945A1 (en)
ZA (1) ZA202002568B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022514702A (en) * 2018-12-21 2022-02-14 オーエスイー・イミュノセラピューティクス Bifunctional anti-PD-1 / IL-7 molecule
CN114080397A (en) 2019-05-17 2022-02-22 Xencor股份有限公司 IL-7-FC fusion proteins
KR102400884B1 (en) * 2019-11-15 2022-05-23 주식회사 제넥신 Fusion protein comprising modified interleukin-7 and interleukin-2 and use thereof
WO2021209402A2 (en) * 2020-04-15 2021-10-21 F. Hoffmann-La Roche Ag Immunoconjugates
WO2022020637A1 (en) * 2020-07-22 2022-01-27 Nektar Therapeutics Il-7 receptor agonist composition and related methods and uses
KR20230129441A (en) 2020-12-17 2023-09-08 오제 이뮈노테라프틱스 Bifunctional anti-PD1/IL-7 molecule
KR20240041379A (en) * 2021-07-09 2024-03-29 브라이트 피크 테라퓨틱스 아게 Checkpoint inhibitors conjugated to IL-2 and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
AU2002240818C1 (en) * 2001-03-14 2008-11-06 Agilent Technologies, Inc. MHC molecule constructs and their uses for diagnosis and therapy
CN101072793B (en) * 2004-12-09 2012-06-20 默克专利有限公司 Il-7 variants with reduced immunogenicity
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
MX363905B (en) * 2006-06-12 2019-04-08 Aptevo Res & Development Llc Single-chain multivalent binding proteins with effector function.
KR101361416B1 (en) * 2008-10-08 2014-02-21 인트렉손 코포레이션 Engineered cells expressing multiple immunomodulators and uses thereof
CN103038343A (en) * 2010-03-23 2013-04-10 英特瑞克斯顿股份有限公司 Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof.
CN104768969B (en) * 2012-09-13 2021-04-16 百时美施贵宝公司 Fibronectin based scaffold domain proteins that bind to myostatin
AU2015306231B2 (en) * 2014-08-18 2019-11-21 Apceth Gmbh & Co. Kg Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
PE20190510A1 (en) * 2016-06-13 2019-04-10 I Mab ANTI-PD-L1 ANTIBODIES AND USES OF THE SAME
CN107488229B (en) 2016-06-13 2020-11-17 天境生物科技(上海)有限公司 PD-L1 antibodies and uses thereof
JP7461741B2 (en) * 2016-06-20 2024-04-04 カイマブ・リミテッド Anti-PD-L1 and IL-2 Cytokines
US9567399B1 (en) * 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US20220008515A1 (en) * 2018-11-16 2022-01-13 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor

Also Published As

Publication number Publication date
ZA202002568B (en) 2021-06-30
IL274564A (en) 2020-06-30
AU2020210258A1 (en) 2020-08-20
JP2022101631A (en) 2022-07-06
CN110352202A (en) 2019-10-18
US11401331B2 (en) 2022-08-02
BR112020010536A2 (en) 2020-12-01
EA202091054A1 (en) 2020-12-24
WO2019144945A1 (en) 2019-08-01
AU2019203918A1 (en) 2019-08-08
MX2020005193A (en) 2020-08-20
AU2019203918B2 (en) 2020-04-30
US20190352405A1 (en) 2019-11-21
KR20200058322A (en) 2020-05-27
JP2021506748A (en) 2021-02-22
CA3082975A1 (en) 2019-08-19
JP7102670B2 (en) 2022-07-20
EP3568417A1 (en) 2019-11-20
EP3568417A4 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
IL276950A (en) Anti-cd73 antibodies and uses thereof
IL273411A (en) Anti-pd-l1 antibody and uses thereof
ZA201902533B (en) Anti-pd-l1 antibodies and variants
ZA202006904B (en) Anti-il-4r antibody and use thereof
IL278846A (en) Anti-cd3 antibodies and uses thereof
SG11202100746WA (en) Anti-tigit antibody and use thereof
IL274564A (en) Anti-pd-l1 antibody and il-7 fusions
IL279455A (en) Anti-pd-1 antibodies and uses thereof
IL282968A (en) Anti-nkg2a antibodies and uses thereof
IL275734B (en) Anti-pd-l1 antibodies and uses thereof
SG11202104240TA (en) Cll1-targeting antibody and application thereof
ZA202006066B (en) Anti-hla-g antibodies and use thereof
ZA202006255B (en) Anti-pd-l1 antibody and use thereof
IL275826A (en) Anti-mct1 antibodies and uses thereof
IL268051A (en) Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
IL281297A (en) Anti-npr1 antibodies and uses thereof
IL282708A (en) Anti-tim-3 antibodies and their use
IL282707A (en) Anti-tim-3 antibodies and their use
IL280321A (en) Anti-cxcr2 antibodies and uses thereof
IL277330A (en) Anti-il-27 antibodies and uses thereof
IL285569A (en) Anti-pd-l1 antibody and use thereof
IL276675A (en) Anti-pd-1 antibodies and uses thereof
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL277075A (en) Anti-phf-tau antibodies and uses thereof
IL276548A (en) Bcma-binding antibodies and uses thereof